Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570359 | 0.82 | ACP3 (0.50) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL9776265 | 0.82 | ACP3 (0.50) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL30903830 | 0.82 | ACP3 (0.50) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL1047627 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL29907993 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL29580255 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL2986939 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL13168657 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL4214299 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 | |
| SCHEMBL343233 | 0.78 | ACP3 (0.47) | ACP3CNR2P2RX7OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2533778-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | LEXICON PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2496231-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF CANCER | Lexicon Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2009002964-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002970-A1 | COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1984344-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| CN-1925855-A | Compounds and methods for development of Ret modulators | PLEXXIKON INC (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1696920-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | ACP3 1130/4885CNR2 498/4885P2RX7 1501/4885 |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | TPH1, TPH2, HNMT | ACP3 785/4885CNR2 709/4885P2RX7 4097/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | ACP3 2288/4885CNR2 224/4885P2RX7 1238/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | ACP3 1151/4885CNR2 3976/4885P2RX7 3175/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | ACP3 97/4885CNR2 635/4885P2RX7 1894/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | ACP3 920/4885CNR2 4513/4885P2RX7 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.